Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 15/20 | 0.54 |
| ▸ | THRA | P10827 | 13/20 | 0.54 |
| ▸ | RORC | P51449 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5387736 | 0.89 | THRB (0.56) | THRBTHRARORCMTNR1BMEN1 | |
| SCHEMBL4359309 | 0.86 | THRA (0.71) | THRBTHRAMTNR1B | |
| SCHEMBL4523206 | 0.85 | THRB (0.51) | THRBTHRARORC | |
| SCHEMBL4524227 | 0.85 | THRB (0.77) | THRBTHRARORC | |
| SCHEMBL5406589 | 0.84 | THRB (0.58) | THRBTHRARORCMTNR1BMEN1 | |
| SCHEMBL5392813 | 0.84 | THRB (0.53) | THRBTHRARORCMTNR1BMEN1 | |
| SCHEMBL5393176 | 0.82 | THRB (0.57) | THRBTHRARORCMTNR1BMEN1 | |
| SCHEMBL5385212 | 0.81 | THRB (0.52) | THRBTHRARORCSMN1; SMN2MTNR1B | |
| SCHEMBL5387560 | 0.81 | THRB (0.52) | THRBTHRARORCMTNR1BMEN1 | |
| SCHEMBL5381964 | 0.79 | THRA (0.60) | THRBTHRAMTNR1BMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199265-B2 | Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones | KARO BIO AB (SE) | 2007-04-03 | — | — | US | claimed |
| US-20040097589-A1 | Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones | KARO BIO AB (SE) | 2004-05-20 | — | — | US | claimed |
| EP-1296936-A1 | THYROID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF DISORDERS INFLUENCED BY THYROID HORMONES | KARO BIO AB (SE) | 2003-04-02 | — | — | EP | claimed |
| WO-2001098256-A1 | THYROID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF DISORDERS INFLUENCED BY THYROID HORMONES | KARO BIO AB (SE) | 2001-12-27 | — | — | WO | claimed |
| WO-2009080835-A1 | THYROMIMETRIC COMPOUNDS IN TREATMENT OF DISEASE RELATED TO SONIC HEDGEHOG SIGNALLING | KARO BIO AB (SE) | 2009-07-02 | — | — | WO | disclosed |
| US-7199265-B2 | Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones | KARO BIO AB (SE) | 2007-04-03 | — | — | US | disclosed |
| US-20040097589-A1 | Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones | KARO BIO AB (SE) | 2004-05-20 | — | — | US | disclosed |
| EP-1296936-A1 | THYROID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF DISORDERS INFLUENCED BY THYROID HORMONES | KARO BIO AB (SE) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001098256-A1 | THYROID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF DISORDERS INFLUENCED BY THYROID HORMONES | KARO BIO AB (SE) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097589-A1 | Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones | TSHR, THRA, THRB | THRB 3/4885THRA 2/4885RORC 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.